The Priority Review

The stream · Daily digest

The stream: Monday, November 16, 2026

10 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 8

  1. AmyriAD acquires AD04 Alzheimer's program from ADvantage

    AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.

    Source: Company press release (PR Newswire), November 16, 2026

  2. Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes

    The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.

    Source: ClinicalTrials.gov registry record, November 16, 2026

  3. Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction

    The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.

    Source: ClinicalTrials.gov registry record, November 16, 2026

  4. AstraZeneca posts results of L-MOCA olaparib maintenance trial

    The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.

    Source: ClinicalTrials.gov results record, November 16, 2026

  5. Novo Nordisk posts results of Phase 3 dasiglucagon vs glucagon study in Asian adults with T1D

    The study, completed with 38 participants, compared dasiglucagon and glucagon for treating severe hypoglycaemia in Asian adults with type 1 diabetes. Results were first posted on ClinicalTrials.gov on November 16, 2026.

    Source: ClinicalTrials.gov results record, November 16, 2026

  6. Novo Nordisk posts results of Phase 3 liraglutide trial in children with obesity

    Results for the 56-week, double-blind, randomized, placebo-controlled trial were first posted on ClinicalTrials.gov on November 16, 2026. The study enrolled 82 children aged 6 to below 12 years to evaluate the effect and safety of liraglutide 3.0 mg on weight management.

    Source: ClinicalTrials.gov results record, November 16, 2026

  7. Roche Diagnostics makes Endotrophin research prototype assay available on cobas e801

    The assay, a sandwich immunoassay, quantifies the intact 77-amino-acid Endotrophin hormone at Nordic Bioscience's CLIA lab. It has been measured in more than 50,000 patients with cardio-kidney-metabolic disease.

    Source: Company press release (PR Newswire), November 16, 2026

  8. Ribupatide shows significant weight loss in adults without diabetes

    In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.

    Source: PubMed record of a Phase III journal article, November 16, 2026

Approvals · 1

  1. FDA approves giredestrant with everolimus for ESR1-mutated breast cancer

    On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.

    Source: FDA approval notification, November 16, 2026

Policy · 1

  1. CMS reports FY 2026 improper payment rates below 10% threshold

    CMS estimates Original Medicare improper payment rate at 7.32%, or $33.96 billion, down from 6.55%, or $28.83 billion in FY 2025. Medicare Part C, Part D, Medicaid, CHIP and APTC rates also decline, with most improper payments due to insufficient documentation.

    Source: CMS fact sheet, November 16, 2026